Related Experiment Video
Updated: Feb 1, 2026
06:04
Author Spotlight: Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model
Published on: June 9, 2023
1.5K
Summary
Ibrutinib is a new standard of care for chronic lymphocytic leukemia (CLL). This Bruton's tyrosine kinase (BTK) inhibitor significantly improved progression-free survival compared to traditional chemoimmunotherapy.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Current standard of care involves chemoimmunotherapy, which has limitations.
- Novel targeted therapies are needed to improve patient outcomes.
Discussion:
- Two Phase III clinical trials evaluated ibrutinib in CLL.
- Ibrutinib was assessed as a single agent and in combination with rituximab.
- Comparisons were made against established chemoimmunotherapy regimens.
Key Insights:
- Ibrutinib demonstrated superior progression-free survival in CLL patients.
- The BTK inhibitor showed improved clinical outcomes across treatment arms.
- Results support ibrutinib as a preferred treatment option over chemoimmunotherapy.
Outlook:
- Ibrutinib is poised to become a new standard of care for CLL.
- Further research may explore long-term efficacy and safety profiles.
- Personalized treatment strategies incorporating ibrutinib are anticipated.
Related Concept Videos
01:31Confirmation Biases
8.2K
The confirmation bias is the tendency to focus on information that confirms our existing beliefs and ignore information that is inconsistent with our expectations. For example, if you think that your professor is not very nice, you notice all of the instances of rude behavior exhibited by the professor while ignoring the countless pleasant interactions he is involved in on a daily basis. Have you ever fallen prey to the confirmation bias, either as the source or target of such bias?
8.2K
01:22Protein Folding
127.4K
Overview
127.4K
01:13Induced-fit Model
89.2K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
89.2K
00:46Feedback Inhibition
57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
01:00Enzyme-linked Receptors
86.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.6K
01:20Monohybrid Crosses
239.5K
Overview
239.5K